It is an uncommon autoimmune disease called Lambert-Eaton Myasthenic Syndrome (LEMS) marked by weariness and muscle weakness. The immune system of the body targets the neuromuscular junctions along with the points where nerve cells attach to muscles thus resulting in autoimmune reaction.
Usually, an autoimmune reaction involving the production of antibodies by the body against voltage-gated calcium channels (VGCCs) at the neuromuscular junctions is linked to LEMS.
It is possible for the immune response to cause cancer as result in the generation of antibodies that interfere with neuromuscular transmission.
Proximal muscles, or those closer to the body’s trunk, include the thighs, shoulders, upper arms and hips. Muscle weakening occurs in LEMS.
Epidemiology
It seems like LEMS affects both sexes equally.
LEMS may appear concurrently with or after the cancer diagnosis, or it may occur prior to the SCLC diagnosis.
Small cell lung cancer (SCLC) is the most often linked tumor with an underlying malignancy present in almost 50% of persons diagnosed with LEMS.
Anatomy
Pathophysiology
VGCCs are essential for controlling the release of neurotransmitters into the synaptic cleft from the nerve terminal with help ōf acetylcholine.
Release of Acetylcholine is reduced because of the autoantibodies in LEMS interfering with VGCC function. Muscle weakness and exhaustion are caused due to decreased neuromuscular transmission.
Autoantibodies in LEMS may also target other presynaptic proteins, like P/Q-type calcium channels, in addition to VGCC antibodies.
The amount of acetylcholine produced in response to nerve stimulation is decreased by these autoantibodies because they interfere with the regular calcium influx into the nerve terminal.
Etiology
Voltage-gated calcium channels in the neuromuscular junction are the target of autoantibodies, which are linked to most occurrences of LEMS.
The production of homologous antigens in the tumor cells and the neuromuscular junction is linked to the relationship between LEMS and SCLC.
Small cell lung cancer is the most common underlying malignancy present in about 50% of patients diagnosed with LEMS.
Genetics
Prognostic Factors
The improvement or remission of LEMS symptoms may result in early identification and treatment of the underlying cancer.
More severe symptoms and a worse response to treatment have been linked in some LEMS patients in addition to higher levels of autoantibodies against voltage-gated calcium channels.
Antibody titer monitoring throughout time may provide data about the course of the disease and how well treatment is working.
Clinical History
Age Group:
LEMS primarily affects adults, with the maximum cases diagnosed in individuals between the ages of 50 and 70 years old.
Associated Comorbidity or Activity:
LEMS is an autoimmune disorder, and individuals with LEMS may have other autoimmune conditions concurrently or develop them over time.
Due to muscle weakness, individuals with LEMS may be at increased risk of respiratory complications, such as respiratory insufficiency or pneumonia.
Chronic obstructive pulmonary disease (COPD) and other respiratory conditions may also coexist with LEMS, particularly in individuals with a history of smoking.
Muscle weakness in LEMS can affect cardiac function and may lead to cardiovascular complications.
Acuity of Presentation:
Acute onset may be characterized by sudden muscle weakness and fatigue, which can lead to significant impairment in mobility and daily activities.
Individuals with acute onset LEMS may seek medical attention promptly due to the severity and rapid progression of symptoms.
Subacute onset is more common in LEMS and is often characterized by a gradual progression of symptoms over weeks to months.
Individuals may initially experience mild weakness or fatigue, which progressively worsens over time.
Chronic onset LEMS may be associated with milder symptoms initially, which may be overlooked or attributed to aging.
Physical Examination
Muscle Strength Testing: LEMS typically presents weakness in proximal muscles, such as those in the hips, thighs, shoulders, and upper arms.
Grip Strength: Assessment of grip strength may reveal weakness in hand muscles.
Eye Movements: Evaluation of extraocular muscles may reveal weakness or fatigue, leading to ptosis (drooping eyelid) or diplopia (double vision).
Assessment of Reflexes: Reflexes may be diminished or absent in individuals with LEMS due to impaired neuromuscular transmission.
Assessment of Autonomic Symptoms: Inquire about symptoms of autonomic dysfunction, such as dry mouth, constipation, erectile dysfunction, or impaired sweating.
Examination for Autonomic Signs: Assess for signs of autonomic dysfunction, such as pupillary abnormalities, orthostatic hypotension, or abnormal sweating patterns.
Ocular Examination: Drooping of one or both eyelids (ptosis) may be observed, particularly after sustained activity or toward the end of the day.
Respiratory Assessment: In severe cases of LEMS, respiratory muscle weakness may lead to respiratory insufficiency or difficulty breathing.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Myasthenia Gravis (MG): Myasthenia Gravis is an autoimmune disorder characterized by muscle weakness and fatigability, but it typically presents with symptoms of ocular weakness and generalized muscle weakness that worsens with activity.
Motor Neuron Diseases: Conditions such as amyotrophic lateral sclerosis (ALS) or spinal muscular atrophy (SMA) may initially present with muscle weakness and fatigue.
Peripheral Neuropathies: Peripheral neuropathies, including immune-mediated neuropathies, diabetic neuropathy, or Charcot-Marie-Tooth disease, may cause muscle weakness and sensory deficits.
Myopathies: Muscle disorders such as polymyositis, dermatomyositis, or inclusion body myositis may present with muscle weakness but typically lack the characteristic autonomic symptoms seen in LEMS.
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Treatment of Underlying Malignancy: For individuals with LEMS associated with an underlying malignancy, such as small cell lung cancer (SCLC), treatment of the cancer is essential. This may include surgery, chemotherapy, radiation therapy, or targeted therapies depending on the type and stage of the malignancy.
Physical Therapy: Physical therapy can help maintain muscle strength, improve mobility, and enhance overall function in individuals with LEMS.
Respiratory Support: For individuals with respiratory muscle weakness or respiratory insufficiency, respiratory support such as non-invasive ventilation or mechanical ventilation may be necessary.
Management of Autonomic Symptoms: Symptomatic treatment of autonomic symptoms such as dry mouth, constipation, or erectile dysfunction may be necessary to improve quality of life.
Home Environment: Ensure that the home is accessible and free from hazards that may increase the risk of falls or injuries. Install handrails, grab bars, and ramps as needed to facilitate safe movement throughout the home.
Adaptive Equipment: Consider the use of assistive devices such as walkers, canes, or wheelchairs to improve mobility and reduce the risk of falls.
Assistive Technology: Explore the use of assistive technology devices, such as lift chairs, stair lifts, or automatic door openers, to improve independence and accessibility within the home.
Ergonomic Workstation: Modify the workstation to reduce strain and fatigue. Ensure that the workstation is ergonomically designed with adjustable furniture, proper lighting, and supportive seating to optimize comfort and productivity.
Accessible Vehicles: Consider the use of accessible vehicles or vehicle modifications, such as wheelchair ramps or lifts, to facilitate transportation for individuals with mobility limitations.
Use of Potassium Channel Blockers
Amifampridine: They are potassium channel blockers prolong action potential duration, leading to enhanced release of acetylcholine at the neuromuscular junction.
They are considered the first-line symptomatic treatment for LEMS and can improve muscle strength and reduce fatigability.
Use of Cholinergic Agonists
Pyridostigmine: It is an acetylcholinesterase inhibitor, which means it blocks the breakdown of acetylcholine, thereby increasing its concentration at the neuromuscular junction. This action enhances neuromuscular transmission and can potentially alleviate muscle weakness and fatigue.
Guanidine: They act by increasing the release of acetylcholine from nerve terminals, thereby enhancing neuromuscular transmission. It also blocks potassium channels, which may contribute to its effects on improving muscle strength.
Use of Immunosuppressants
Prednisone: It is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by inhibiting the production of pro-inflammatory cytokines, suppressing immune cell activation and migration, and altering gene expression involved in the immune response.
Azathioprine: It is an immunosuppressive medication that inhibits purine synthesis and interferes with DNA replication and cell proliferation, particularly in rapidly dividing immune cells such as lymphocytes.
Plasmapheresis: Blood is withdrawn from the patient through a catheter, and the plasma is separated from the blood cells using a centrifuge or filtration system.
The plasma containing autoantibodies and other potentially harmful substances is removed, while the blood cells are retained.
The removed plasma is replaced with a replacement fluid (such as albumin or saline solution) or donor plasma. The replacement fluid serves to maintain blood volume and prevent hypovolemia.
Diagnostic Phase: Prompt recognition of LEMS based on clinical presentation, electromyography (EMG) findings, and detection of voltage-gated calcium channel antibodies.
Acute Phase: Initiate symptomatic treatment to alleviate muscle weakness and fatigue to improve neuromuscular transmission.
Stabilization Phase: Initiate immunomodulatory therapy, such as corticosteroids, intravenous immunoglobulin (IVIG), or other immunosuppressive medications, to suppress the autoimmune response and stabilize the disease.
Rehabilitation Phase: Implement a comprehensive physical therapy program to improve muscle strength, mobility, and functional independence.
Provide occupational therapy to address activities of daily living (ADLs), assistive device training, and adaptive strategies to optimize independence and participation.
»
Home » CAD » Lambert-Eaton Myasthenic Syndrome (LEMS)
Lambert-Eaton Myasthenic Syndrome (LEMS)
Updated :
July 17, 2024
It is an uncommon autoimmune disease called Lambert-Eaton Myasthenic Syndrome (LEMS) marked by weariness and muscle weakness. The immune system of the body targets the neuromuscular junctions along with the points where nerve cells attach to muscles thus resulting in autoimmune reaction.
Usually, an autoimmune reaction involving the production of antibodies by the body against voltage-gated calcium channels (VGCCs) at the neuromuscular junctions is linked to LEMS.
It is possible for the immune response to cause cancer as result in the generation of antibodies that interfere with neuromuscular transmission.
Proximal muscles, or those closer to the body’s trunk, include the thighs, shoulders, upper arms and hips. Muscle weakening occurs in LEMS.
It seems like LEMS affects both sexes equally.
LEMS may appear concurrently with or after the cancer diagnosis, or it may occur prior to the SCLC diagnosis.
Small cell lung cancer (SCLC) is the most often linked tumor with an underlying malignancy present in almost 50% of persons diagnosed with LEMS.
VGCCs are essential for controlling the release of neurotransmitters into the synaptic cleft from the nerve terminal with help ōf acetylcholine.
Release of Acetylcholine is reduced because of the autoantibodies in LEMS interfering with VGCC function. Muscle weakness and exhaustion are caused due to decreased neuromuscular transmission.
Autoantibodies in LEMS may also target other presynaptic proteins, like P/Q-type calcium channels, in addition to VGCC antibodies.
The amount of acetylcholine produced in response to nerve stimulation is decreased by these autoantibodies because they interfere with the regular calcium influx into the nerve terminal.
Voltage-gated calcium channels in the neuromuscular junction are the target of autoantibodies, which are linked to most occurrences of LEMS.
The production of homologous antigens in the tumor cells and the neuromuscular junction is linked to the relationship between LEMS and SCLC.
Small cell lung cancer is the most common underlying malignancy present in about 50% of patients diagnosed with LEMS.
The improvement or remission of LEMS symptoms may result in early identification and treatment of the underlying cancer.
More severe symptoms and a worse response to treatment have been linked in some LEMS patients in addition to higher levels of autoantibodies against voltage-gated calcium channels.
Antibody titer monitoring throughout time may provide data about the course of the disease and how well treatment is working.
Age Group:
LEMS primarily affects adults, with the maximum cases diagnosed in individuals between the ages of 50 and 70 years old.
Associated Comorbidity or Activity:
LEMS is an autoimmune disorder, and individuals with LEMS may have other autoimmune conditions concurrently or develop them over time.
Due to muscle weakness, individuals with LEMS may be at increased risk of respiratory complications, such as respiratory insufficiency or pneumonia.
Chronic obstructive pulmonary disease (COPD) and other respiratory conditions may also coexist with LEMS, particularly in individuals with a history of smoking.
Muscle weakness in LEMS can affect cardiac function and may lead to cardiovascular complications.
Acuity of Presentation:
Acute onset may be characterized by sudden muscle weakness and fatigue, which can lead to significant impairment in mobility and daily activities.
Individuals with acute onset LEMS may seek medical attention promptly due to the severity and rapid progression of symptoms.
Subacute onset is more common in LEMS and is often characterized by a gradual progression of symptoms over weeks to months.
Individuals may initially experience mild weakness or fatigue, which progressively worsens over time.
Chronic onset LEMS may be associated with milder symptoms initially, which may be overlooked or attributed to aging.
Muscle Strength Testing: LEMS typically presents weakness in proximal muscles, such as those in the hips, thighs, shoulders, and upper arms.
Grip Strength: Assessment of grip strength may reveal weakness in hand muscles.
Eye Movements: Evaluation of extraocular muscles may reveal weakness or fatigue, leading to ptosis (drooping eyelid) or diplopia (double vision).
Assessment of Reflexes: Reflexes may be diminished or absent in individuals with LEMS due to impaired neuromuscular transmission.
Assessment of Autonomic Symptoms: Inquire about symptoms of autonomic dysfunction, such as dry mouth, constipation, erectile dysfunction, or impaired sweating.
Examination for Autonomic Signs: Assess for signs of autonomic dysfunction, such as pupillary abnormalities, orthostatic hypotension, or abnormal sweating patterns.
Ocular Examination: Drooping of one or both eyelids (ptosis) may be observed, particularly after sustained activity or toward the end of the day.
Respiratory Assessment: In severe cases of LEMS, respiratory muscle weakness may lead to respiratory insufficiency or difficulty breathing.
Myasthenia Gravis (MG): Myasthenia Gravis is an autoimmune disorder characterized by muscle weakness and fatigability, but it typically presents with symptoms of ocular weakness and generalized muscle weakness that worsens with activity.
Motor Neuron Diseases: Conditions such as amyotrophic lateral sclerosis (ALS) or spinal muscular atrophy (SMA) may initially present with muscle weakness and fatigue.
Peripheral Neuropathies: Peripheral neuropathies, including immune-mediated neuropathies, diabetic neuropathy, or Charcot-Marie-Tooth disease, may cause muscle weakness and sensory deficits.
Myopathies: Muscle disorders such as polymyositis, dermatomyositis, or inclusion body myositis may present with muscle weakness but typically lack the characteristic autonomic symptoms seen in LEMS.
Treatment of Underlying Malignancy: For individuals with LEMS associated with an underlying malignancy, such as small cell lung cancer (SCLC), treatment of the cancer is essential. This may include surgery, chemotherapy, radiation therapy, or targeted therapies depending on the type and stage of the malignancy.
Physical Therapy: Physical therapy can help maintain muscle strength, improve mobility, and enhance overall function in individuals with LEMS.
Respiratory Support: For individuals with respiratory muscle weakness or respiratory insufficiency, respiratory support such as non-invasive ventilation or mechanical ventilation may be necessary.
Management of Autonomic Symptoms: Symptomatic treatment of autonomic symptoms such as dry mouth, constipation, or erectile dysfunction may be necessary to improve quality of life.
Home Environment: Ensure that the home is accessible and free from hazards that may increase the risk of falls or injuries. Install handrails, grab bars, and ramps as needed to facilitate safe movement throughout the home.
Adaptive Equipment: Consider the use of assistive devices such as walkers, canes, or wheelchairs to improve mobility and reduce the risk of falls.
Assistive Technology: Explore the use of assistive technology devices, such as lift chairs, stair lifts, or automatic door openers, to improve independence and accessibility within the home.
Ergonomic Workstation: Modify the workstation to reduce strain and fatigue. Ensure that the workstation is ergonomically designed with adjustable furniture, proper lighting, and supportive seating to optimize comfort and productivity.
Accessible Vehicles: Consider the use of accessible vehicles or vehicle modifications, such as wheelchair ramps or lifts, to facilitate transportation for individuals with mobility limitations.
Amifampridine: They are potassium channel blockers prolong action potential duration, leading to enhanced release of acetylcholine at the neuromuscular junction.
They are considered the first-line symptomatic treatment for LEMS and can improve muscle strength and reduce fatigability.
Pyridostigmine: It is an acetylcholinesterase inhibitor, which means it blocks the breakdown of acetylcholine, thereby increasing its concentration at the neuromuscular junction. This action enhances neuromuscular transmission and can potentially alleviate muscle weakness and fatigue.
Guanidine: They act by increasing the release of acetylcholine from nerve terminals, thereby enhancing neuromuscular transmission. It also blocks potassium channels, which may contribute to its effects on improving muscle strength.
Prednisone: It is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by inhibiting the production of pro-inflammatory cytokines, suppressing immune cell activation and migration, and altering gene expression involved in the immune response.
Azathioprine: It is an immunosuppressive medication that inhibits purine synthesis and interferes with DNA replication and cell proliferation, particularly in rapidly dividing immune cells such as lymphocytes.
Plasmapheresis: Blood is withdrawn from the patient through a catheter, and the plasma is separated from the blood cells using a centrifuge or filtration system.
The plasma containing autoantibodies and other potentially harmful substances is removed, while the blood cells are retained.
The removed plasma is replaced with a replacement fluid (such as albumin or saline solution) or donor plasma. The replacement fluid serves to maintain blood volume and prevent hypovolemia.
Diagnostic Phase: Prompt recognition of LEMS based on clinical presentation, electromyography (EMG) findings, and detection of voltage-gated calcium channel antibodies.
Acute Phase: Initiate symptomatic treatment to alleviate muscle weakness and fatigue to improve neuromuscular transmission.
Stabilization Phase: Initiate immunomodulatory therapy, such as corticosteroids, intravenous immunoglobulin (IVIG), or other immunosuppressive medications, to suppress the autoimmune response and stabilize the disease.
Rehabilitation Phase: Implement a comprehensive physical therapy program to improve muscle strength, mobility, and functional independence.
Provide occupational therapy to address activities of daily living (ADLs), assistive device training, and adaptive strategies to optimize independence and participation.
It is an uncommon autoimmune disease called Lambert-Eaton Myasthenic Syndrome (LEMS) marked by weariness and muscle weakness. The immune system of the body targets the neuromuscular junctions along with the points where nerve cells attach to muscles thus resulting in autoimmune reaction.
Usually, an autoimmune reaction involving the production of antibodies by the body against voltage-gated calcium channels (VGCCs) at the neuromuscular junctions is linked to LEMS.
It is possible for the immune response to cause cancer as result in the generation of antibodies that interfere with neuromuscular transmission.
Proximal muscles, or those closer to the body’s trunk, include the thighs, shoulders, upper arms and hips. Muscle weakening occurs in LEMS.
It seems like LEMS affects both sexes equally.
LEMS may appear concurrently with or after the cancer diagnosis, or it may occur prior to the SCLC diagnosis.
Small cell lung cancer (SCLC) is the most often linked tumor with an underlying malignancy present in almost 50% of persons diagnosed with LEMS.
VGCCs are essential for controlling the release of neurotransmitters into the synaptic cleft from the nerve terminal with help ōf acetylcholine.
Release of Acetylcholine is reduced because of the autoantibodies in LEMS interfering with VGCC function. Muscle weakness and exhaustion are caused due to decreased neuromuscular transmission.
Autoantibodies in LEMS may also target other presynaptic proteins, like P/Q-type calcium channels, in addition to VGCC antibodies.
The amount of acetylcholine produced in response to nerve stimulation is decreased by these autoantibodies because they interfere with the regular calcium influx into the nerve terminal.
Voltage-gated calcium channels in the neuromuscular junction are the target of autoantibodies, which are linked to most occurrences of LEMS.
The production of homologous antigens in the tumor cells and the neuromuscular junction is linked to the relationship between LEMS and SCLC.
Small cell lung cancer is the most common underlying malignancy present in about 50% of patients diagnosed with LEMS.
The improvement or remission of LEMS symptoms may result in early identification and treatment of the underlying cancer.
More severe symptoms and a worse response to treatment have been linked in some LEMS patients in addition to higher levels of autoantibodies against voltage-gated calcium channels.
Antibody titer monitoring throughout time may provide data about the course of the disease and how well treatment is working.
Age Group:
LEMS primarily affects adults, with the maximum cases diagnosed in individuals between the ages of 50 and 70 years old.
Associated Comorbidity or Activity:
LEMS is an autoimmune disorder, and individuals with LEMS may have other autoimmune conditions concurrently or develop them over time.
Due to muscle weakness, individuals with LEMS may be at increased risk of respiratory complications, such as respiratory insufficiency or pneumonia.
Chronic obstructive pulmonary disease (COPD) and other respiratory conditions may also coexist with LEMS, particularly in individuals with a history of smoking.
Muscle weakness in LEMS can affect cardiac function and may lead to cardiovascular complications.
Acuity of Presentation:
Acute onset may be characterized by sudden muscle weakness and fatigue, which can lead to significant impairment in mobility and daily activities.
Individuals with acute onset LEMS may seek medical attention promptly due to the severity and rapid progression of symptoms.
Subacute onset is more common in LEMS and is often characterized by a gradual progression of symptoms over weeks to months.
Individuals may initially experience mild weakness or fatigue, which progressively worsens over time.
Chronic onset LEMS may be associated with milder symptoms initially, which may be overlooked or attributed to aging.
Muscle Strength Testing: LEMS typically presents weakness in proximal muscles, such as those in the hips, thighs, shoulders, and upper arms.
Grip Strength: Assessment of grip strength may reveal weakness in hand muscles.
Eye Movements: Evaluation of extraocular muscles may reveal weakness or fatigue, leading to ptosis (drooping eyelid) or diplopia (double vision).
Assessment of Reflexes: Reflexes may be diminished or absent in individuals with LEMS due to impaired neuromuscular transmission.
Assessment of Autonomic Symptoms: Inquire about symptoms of autonomic dysfunction, such as dry mouth, constipation, erectile dysfunction, or impaired sweating.
Examination for Autonomic Signs: Assess for signs of autonomic dysfunction, such as pupillary abnormalities, orthostatic hypotension, or abnormal sweating patterns.
Ocular Examination: Drooping of one or both eyelids (ptosis) may be observed, particularly after sustained activity or toward the end of the day.
Respiratory Assessment: In severe cases of LEMS, respiratory muscle weakness may lead to respiratory insufficiency or difficulty breathing.
Myasthenia Gravis (MG): Myasthenia Gravis is an autoimmune disorder characterized by muscle weakness and fatigability, but it typically presents with symptoms of ocular weakness and generalized muscle weakness that worsens with activity.
Motor Neuron Diseases: Conditions such as amyotrophic lateral sclerosis (ALS) or spinal muscular atrophy (SMA) may initially present with muscle weakness and fatigue.
Peripheral Neuropathies: Peripheral neuropathies, including immune-mediated neuropathies, diabetic neuropathy, or Charcot-Marie-Tooth disease, may cause muscle weakness and sensory deficits.
Myopathies: Muscle disorders such as polymyositis, dermatomyositis, or inclusion body myositis may present with muscle weakness but typically lack the characteristic autonomic symptoms seen in LEMS.
Treatment of Underlying Malignancy: For individuals with LEMS associated with an underlying malignancy, such as small cell lung cancer (SCLC), treatment of the cancer is essential. This may include surgery, chemotherapy, radiation therapy, or targeted therapies depending on the type and stage of the malignancy.
Physical Therapy: Physical therapy can help maintain muscle strength, improve mobility, and enhance overall function in individuals with LEMS.
Respiratory Support: For individuals with respiratory muscle weakness or respiratory insufficiency, respiratory support such as non-invasive ventilation or mechanical ventilation may be necessary.
Management of Autonomic Symptoms: Symptomatic treatment of autonomic symptoms such as dry mouth, constipation, or erectile dysfunction may be necessary to improve quality of life.
Home Environment: Ensure that the home is accessible and free from hazards that may increase the risk of falls or injuries. Install handrails, grab bars, and ramps as needed to facilitate safe movement throughout the home.
Adaptive Equipment: Consider the use of assistive devices such as walkers, canes, or wheelchairs to improve mobility and reduce the risk of falls.
Assistive Technology: Explore the use of assistive technology devices, such as lift chairs, stair lifts, or automatic door openers, to improve independence and accessibility within the home.
Ergonomic Workstation: Modify the workstation to reduce strain and fatigue. Ensure that the workstation is ergonomically designed with adjustable furniture, proper lighting, and supportive seating to optimize comfort and productivity.
Accessible Vehicles: Consider the use of accessible vehicles or vehicle modifications, such as wheelchair ramps or lifts, to facilitate transportation for individuals with mobility limitations.
Amifampridine: They are potassium channel blockers prolong action potential duration, leading to enhanced release of acetylcholine at the neuromuscular junction.
They are considered the first-line symptomatic treatment for LEMS and can improve muscle strength and reduce fatigability.
Pyridostigmine: It is an acetylcholinesterase inhibitor, which means it blocks the breakdown of acetylcholine, thereby increasing its concentration at the neuromuscular junction. This action enhances neuromuscular transmission and can potentially alleviate muscle weakness and fatigue.
Guanidine: They act by increasing the release of acetylcholine from nerve terminals, thereby enhancing neuromuscular transmission. It also blocks potassium channels, which may contribute to its effects on improving muscle strength.
Prednisone: It is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by inhibiting the production of pro-inflammatory cytokines, suppressing immune cell activation and migration, and altering gene expression involved in the immune response.
Azathioprine: It is an immunosuppressive medication that inhibits purine synthesis and interferes with DNA replication and cell proliferation, particularly in rapidly dividing immune cells such as lymphocytes.
Plasmapheresis: Blood is withdrawn from the patient through a catheter, and the plasma is separated from the blood cells using a centrifuge or filtration system.
The plasma containing autoantibodies and other potentially harmful substances is removed, while the blood cells are retained.
The removed plasma is replaced with a replacement fluid (such as albumin or saline solution) or donor plasma. The replacement fluid serves to maintain blood volume and prevent hypovolemia.
Diagnostic Phase: Prompt recognition of LEMS based on clinical presentation, electromyography (EMG) findings, and detection of voltage-gated calcium channel antibodies.
Acute Phase: Initiate symptomatic treatment to alleviate muscle weakness and fatigue to improve neuromuscular transmission.
Stabilization Phase: Initiate immunomodulatory therapy, such as corticosteroids, intravenous immunoglobulin (IVIG), or other immunosuppressive medications, to suppress the autoimmune response and stabilize the disease.
Rehabilitation Phase: Implement a comprehensive physical therapy program to improve muscle strength, mobility, and functional independence.
Provide occupational therapy to address activities of daily living (ADLs), assistive device training, and adaptive strategies to optimize independence and participation.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
